Advancedmolecular
DNA Methylation
Overview
DNA methylation (5-methylcytosine, 'the fifth base') occurs at CpG dinucleotides in mammals: ~70-80% methylated genome-wide, but CpG islands at promoters are usually unmethylated when genes are active. DNMT3A/3B establish marks, DNMT1 maintains them, TET enzymes remove them. Methylation silences transposons, enables imprinting and X-inactivation, and its disruption drives cancer.
Learning objectives
- Describe CpG methylation patterns
- Explain DNMT and TET enzyme functions
- Describe how methylation silences genes
- Explain methylation in development and cancer
The CpG landscape
Mammalian genomes are CpG-poor (deamination of methyl-C over evolution) except CpG islands: dense clusters at ~60% of promoters. Methylated island = silent promoter; unmethylated = permissive. Global methylation silences transposons and repetitive DNA that threaten genome stability.
CpG island methylation status is the on/off switch read at most gene promoters.
The enzyme cycle
DNMT3A/3B: de novo methylation (development, imprinting). DNMT1: maintenance at replication, copying marks to daughter strands. TET1/2/3: oxidize 5mC to 5hmC/5fC/5caC, leading to active demethylation. 5hmC is also a stable mark in neurons with its own readers.
TET enzymes are Fe(II)/alpha-KG dioxygenases enhanced by ascorbate: metabolism meets epigenetics.
How methylation silences
Directly: methyl groups block some transcription factors. Indirectly: MBD proteins (MeCP2, MBD2) bind methyl-CpG and recruit HDACs/corepressors, compacting chromatin. Either route converges on a closed, silent locus.
Gene-body methylation correlates with ACTIVE transcription; context (promoter vs body) decides.
Development and disease
Two waves of demethylation/remethylation reprogram the germline and early embryo. In cancer: global hypomethylation (instability, oncogene activation) plus focal tumor-suppressor hypermethylation (p16, MLH1, BRCA1). Liquid-biopsy methylation panels now detect cancers from blood.
Tumor-specific methylation patterns in cell-free DNA enable multi-cancer early detection tests.
Key points
- 5-methylcytosine at CpGs; islands at promoters switch genes off when methylated
- DNMT3s establish, DNMT1 maintains, TETs remove
- Silencing via TF blocking and MBD-recruited chromatin compaction
- Reprogrammed in embryo; disrupted in cancer (biomarker opportunity)
Common misconceptions
✓ Truth: Promoter methylation silences, but gene-body methylation marks active transcription: location matters.
✓ Truth: TET-mediated demethylation actively rewrites them, especially in development and neurons.
Practice questions
Q1. Maintenance DNA methylation is performed by
- DNMT3A
- DNMT1
- TET2
- MBD2
DNMT1 copies methylation patterns to daughter strands during replication.
Q2. CpG island hypermethylation at a tumor-suppressor promoter causes
- Activation
- Silencing of the tumor suppressor
- Nothing
- Amplification
Methylation recruits MBD proteins and HDACs, closing the promoter.
Q3. TET enzymes function to
- Add methyl groups
- Oxidize 5mC toward demethylation
- Bind RNA
- Cut DNA
TETs convert 5mC to 5hmC/5fC/5caC, enabling active demethylation.
Click a question to reveal the answer and explanation.
Frequently asked questions
Why are CpG islands unmethylated at active promoters?
Transcription factor binding and protective factors (like CXXC proteins) exclude DNMTs; methylation would recruit silencers.
What is 5hmC?
5-hydroxymethylcytosine: TET's first oxidation product, abundant in brain, both a demethylation intermediate and a functional mark.
How does azacitidine work?
This cytosine analog incorporates into DNA and traps DNMTs, causing passive demethylation and reactivating silenced genes.